NCT07365462
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 35 → 48 locations
- Notable Eligibility criteria expanded, about 9 words
- Primary endpoints: details revised at 1 of 1 entry
- Trial sites expanded: 18 → 35 locations
- Minor Study sites: 17 to 18v4
- Minor Trial sites expanded: 6 → 17 locations
- Start date: Jan 23, 2026 to Feb 6, 2026
- Notable Recruitment opened
- Trial sites expanded: 0 → 6 locations
- Start date changed from estimate of Jan 2026 to Jan 23, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 8 Based on the Blinded Central AIMS Video Raters' Assessment
Timeframe: Baseline and Week 8
Secondary (1)
Percentage of Participants Who Are a Clinical Global Impression - Improvement (CGI-I) Responder 1 at Week 8
Arms and interventions
NBI-1065890Experimental
Participants will receive NBI-1065890.
PlaceboPlacebo comparator
Participants will receive placebo matching NBI-1065890.
Drugs: NBI-1065890, Placebo
Sites
48 sites in 6 countries
United States 31, Bulgaria 9, Slovakia 3, Czechia 2, Romania 2, Puerto Rico 1